Risks to Scientific Research

Closing the Doors on Global Research Risks Slowing Scientific Progress

Collaboration with researchers around the world drives the IMF’s mission to achieve a cure for multiple myeloma. More than 90% of the members of the International Myeloma Working Group are foreign-born immigrants to the U.S. or reside in 35 other countries around the globe. “This global intellectual capital is a key element of our success, and the IMF is alarmed by measures that threaten international research collaboration,” writes IMF Chairman Dr. Brian Durie in his blog this week. Click HERE to read.

The European Medicines Agency Adopts a Positive Opinion on Marketing Authorization for Revlimid (lenalidomide)

TOn January 26, 2017, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorization for Revlimid. The CHMP adopted an extension to an existing indication as follows: “Revlimid as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation.” Learn more HERE.

 

Change Your Social Media Banners on World Cancer Day - February 4, 2017Tell Congress to Save Our Health Care

Established by the Paris Charter in the year 2000, World Cancer Day is a global event that takes place every year on February 4th. The International Myeloma Foundation urges you to join us in helping raise awareness and education about cancer by updating your social media banners with the banners available HERE on Saturday, February 4th. World Cancer Day is an ideal opportunity to spread the word and raise the profile of cancer in people’s minds and the world’s media.

 

Nordic Countries Added to Roster of Patient & Family Seminar Sites

Nadia Elkebir, Director of IMF Europe, just wrapped up a tour to finalize upcoming Patient & Family Seminars to be held this fall, one in each of all five of the Nordic countries. Of note, in October 2017, a Patient & Family Seminar will be held in Helsinki, Finland, in collaboration with the Finnish support group: Suomen Syöpäpotilaat. Dr Rafat Abonour will be guest speaker for this event. For more information on the Finnish support group, click HERE.

 

 


We Would Like to Thank Our Sponsors: Takeda Oncology, Celgene, Amgen, and Bristol-Myers Squibb